26/11/2015 12:50:12 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

11/25/20155:59AMBWEuropäische Kommission billigt Abstimmung von Indikationen für Nivolumab unter dem europäischen Marktzulassungsantrag für...
Innovativer aufsichtsbehördlicher Ansatz ermöglicht zeitgleiche Prüfung von Nivolumab für zwei Indikationen, was für eine beschleunigte Verfügbarkeit sorgt Bristol-Myers Squibb Company (NYSE:BMY) gab heute bekannt, dass die Europäische Kommission die Abstimmung von Indikationen für Nivolumab unter dem europäischen... More...>>
11/25/20155:59AMBWLa Commission européenne approuve la réconciliation des indications pour nivolumab dans la demande d’autorisation europé...
L’approche réglementaire novatrice a permis l’examen simultané de nivolumab pour deux indications, accélérant la disponibilité pour les patients Bristol-Myers Squibb Company (NYSE:BMY) a annoncé aujourd’hui que la Commission européenne (CE) a approuvé la réconciliation des indications de nivolumab dans la... More...>>
11/25/20155:59AMBWLa Commissione europea approva la riconciliazione delle indicazioni per nivolumab nel quadro della domanda di autorizzazione ...
Un innovativo approccio normativo ha reso possibile la valutazione contemporanea di nivolumab per due indicazioni, velocizzando la disponibilità del farmaco per i pazienti Bristol-Myers Squibb Company (NYSE: BMY) ha oggi annunciato che la Commissione europea (CE) ha approvato la riconciliazione delle indicazioni relative... More...>>
11/24/20153:03PMTMFWhy Aduro Biotech Is Crashing Today
http://www.fool.com/investing/general/2015/11/24/why-aduro-biotech-is-crashing-today.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/24/20156:59AMBWEuropean Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorization ...
Innovative regulatory approach enabled simultaneous review of nivolumab for two indications, expediting availability to patients Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has approved the reconciliation of indications for nivolumab under the Opdivo European Marketing Authorization... More...>>
11/24/20156:55AMBWBristol-Myers Squibb Announces U.S. Food & Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Trea...
First and only PD-1 immune checkpoint inhibitor approved as a single agent for first-line use in advanced BRAF wild-type melanoma Approval based on Phase 3 trial, CheckMate -066, which demonstrated superior overall survival vs. dacarbazine in first-line treatment of patients with BRAF wild-type advanced melanoma Marks... More...>>
11/23/20157:23PMBWBristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival...
The first and only PD-1 inhibitor approved based on a demonstrated OS benefit in patients with advanced RCC who have received prior anti-angiogenic therapy1 Approval based on CheckMate -025, which demonstrated median OS benefit of 25 months (95% CI: 21.7-NE) for Opdivo vs. 19.6 months (95% CI: 17.6-23.1) for everolimus... More...>>
11/23/20156:00PMTMF5 Dividend Stocks to Buy in November
http://www.fool.com/investing/general/2015/11/23/5-dividend-stocks-to-buy-in-november.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/23/20159:20AMTMFThe FDA Approves Exelixis, Inc's New Cancer Drug
http://www.fool.com/investing/general/2015/11/23/the-fda-approves-exelixis-incs-new-cancer-drug.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/22/20159:12AMTMFBeyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting Back Against Cancer
http://www.fool.com/investing/general/2015/11/22/beyond-chemotherapy-4-unique-ways-drug-developers.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/20/20156:08PMTMFThe Best Healthcare ETF of the Week
http://www.fool.com/investing/general/2015/11/20/the-best-healthcare-etf-of-the-week.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/20/20155:55PMDJNCelldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows
By Ron Winslow The strategy of enlisting the power of the immune system to attack cancer is showing early promise against another tough-to-treat malignancy: the brain cancer called glioblastoma. In the latest development, researchers reported on Friday that a cancer vaccine being developed by Celldex Therapeutics Inc... More...>>
11/18/201512:00PMBWNew Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melan...
First and only PD-1 checkpoint inhibitor to demonstrate two-year overall survival data in a Phase 3 trial, CheckMate -066, with nearly 60% of patients still alive at two years Longest follow-up for the Opdivo + Yervoy Regimen from Study 004 shows three-year overall survival rate of 68% across Phase 1 dosing cohorts Bristol-Myers... More...>>
11/18/201510:18AMTMF5 Things Merck & Co., Inc. Wants You to Know
http://www.fool.com/investing/general/2015/11/18/5-things-merck-co-inc-wants-you-to-know.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/16/20155:03PMBWU.S. Food & Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolu...
Submission based on overall survival data from CheckMate -025, a Phase 3 study comparing Opdivo versus everolimus in this patient population Agency previously granted Opdivo Breakthrough Therapy Designation for this indication Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration... More...>>
11/16/20156:59AMBWData from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir & Ribavirin in Chronic Hepatitis ...
Daclatasvir+sofosbuvir+ribavirin regimen for 12 or 16 weeks achieved SVR12 rates of 88% and 92%, respectively, in genotype 3 patients with advanced fibrosis or cirrhosis Bristol-Myers Squibb Company (NYSE:BMY) today announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza (daclatasvir... More...>>
11/15/20156:00PMTMFExelixis, Inc. Earnings: Riding the Meteor
http://www.fool.com/investing/general/2015/11/15/exelixis-inc-earnings-riding-the-meteor.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/14/20159:40AMTMFWhy Five Prime Therapeutics Rocketed 109% Higher in October
http://www.fool.com/investing/general/2015/11/14/why-five-prime-therapeutics-rocketed-109-higher-in.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/13/20158:41AMTMFHepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
http://www.fool.com/investing/general/2015/11/13/hepatitis-c-treatment-in-2016-will-gilead-sciences.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/12/20156:59AMBWBristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy & in Combination with Ye...
Longest follow-up data for a PD-1 checkpoint inhibitor in a Phase 3 trial, CheckMate -066, evaluating Opdivo in treatment-naïve advanced melanoma, to be presented Three year survival data for the Opdivo + Yervoy Regimen from Phase 1 cohorts of Study 004 to be presented Patient reported outcomes from the Phase 3 CheckMate... More...>>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy151126 12:50